Guided Therapy Systems Keeps Options Open On Tissue Regen Device
Guided Therapy Systems CEO Michael Slayton, PhD, has a history of breaking innovative medical technology, with a primary focus on diagnostic and therapeutic ultrasound applications. He tells In Vivo about the 22-year engineering journey that has led him and the company he founded to the cusp of market launch of a non-invasive tissue regeneration device for musculoskeletal injuries.
You may also be interested in...
Going More Than Skin Deep Into Merz’s Ulthera Acquisition
New Enterprise Associates registered one of its biggest returns ever when Merz agreed to pay up to $600 million for aesthetics company Ulthera. CEO Matthew Likens and lead investor Justin Klein, MD, discuss specifics about the blockbuster deal.
UK LifeSci Funding Boost – Medtech Research And Regulation To Benefit
Rebranded Health Innovation Networks, Biobanks and clinical trials get share of £650m UK funding earmarked to support research, manufacturing, skills development and access to diagnosis and treatment.
UK Pro-Innovation Report Offers Promise For Medtech With MHRA/NICE Alignment
Report to government underlines need for faster, parallel evaluation of medtech and healthtech innovation and recommends bigger role for MHRA alongside work done by approved bodies on UKCA file processing.